EP2373691A4 - Anti-fxi antibodies and methods of use - Google Patents

Anti-fxi antibodies and methods of use

Info

Publication number
EP2373691A4
EP2373691A4 EP09837993A EP09837993A EP2373691A4 EP 2373691 A4 EP2373691 A4 EP 2373691A4 EP 09837993 A EP09837993 A EP 09837993A EP 09837993 A EP09837993 A EP 09837993A EP 2373691 A4 EP2373691 A4 EP 2373691A4
Authority
EP
European Patent Office
Prior art keywords
methods
fxi antibodies
fxi
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09837993A
Other languages
German (de)
French (fr)
Other versions
EP2373691B1 (en
EP2373691A2 (en
Inventor
Andras Gruber
Erik I Tucker
David Gailani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Vanderbilt University
Original Assignee
Oregon Health Science University
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Science University, Vanderbilt University filed Critical Oregon Health Science University
Priority to PL09837993T priority Critical patent/PL2373691T3/en
Priority to SI200931958T priority patent/SI2373691T1/en
Publication of EP2373691A2 publication Critical patent/EP2373691A2/en
Publication of EP2373691A4 publication Critical patent/EP2373691A4/en
Application granted granted Critical
Publication of EP2373691B1 publication Critical patent/EP2373691B1/en
Priority to HRP20190605TT priority patent/HRP20190605T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP09837993.6A 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use Active EP2373691B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL09837993T PL2373691T3 (en) 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use
SI200931958T SI2373691T1 (en) 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use
HRP20190605TT HRP20190605T1 (en) 2008-12-18 2019-03-28 Anti-fxi antibodies and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13859008P 2008-12-18 2008-12-18
PCT/US2009/068768 WO2010080623A2 (en) 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use

Publications (3)

Publication Number Publication Date
EP2373691A2 EP2373691A2 (en) 2011-10-12
EP2373691A4 true EP2373691A4 (en) 2012-10-31
EP2373691B1 EP2373691B1 (en) 2019-01-23

Family

ID=42317079

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09837993.6A Active EP2373691B1 (en) 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use

Country Status (15)

Country Link
US (3) US8388959B2 (en)
EP (1) EP2373691B1 (en)
AU (1) AU2009335643B2 (en)
CA (1) CA2747519C (en)
CY (1) CY1121562T1 (en)
DK (1) DK2373691T3 (en)
ES (1) ES2720594T3 (en)
HR (1) HRP20190605T1 (en)
HU (1) HUE042940T2 (en)
LT (1) LT2373691T (en)
PL (1) PL2373691T3 (en)
PT (1) PT2373691T (en)
SI (1) SI2373691T1 (en)
TR (1) TR201904662T4 (en)
WO (1) WO2010080623A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
SI2373691T1 (en) * 2008-12-18 2019-05-31 Oregon Health & Science University Anti-fxi antibodies and methods of use
CN102600471A (en) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 Target spot for treating septicemia
EP2847228B1 (en) * 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
AU2015373910B2 (en) 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
JOP20200312A1 (en) * 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
RU2757314C2 (en) * 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Antibodies against xi clotting factor
WO2017162791A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (en) 2016-05-25 2018-01-16 諾華公司 Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
TWI752964B (en) 2016-06-14 2022-01-21 美商默沙東藥廠 Anti-coagulation factor xi antibodies
US10654941B2 (en) * 2016-09-20 2020-05-19 Bayer Pharma Aktiengesellschaft Antibodies against factor XI and uses thereof
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
CA3048156A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
CN108409863B (en) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 Anticoagulant factor XI antibodies
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
BR112020010016A2 (en) 2017-11-22 2020-11-10 Novartis Ag reversal binding agents for anti-factor xi / xia antibodies and their uses
CA3108708A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
CA3125303A1 (en) * 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof
EP3957652A4 (en) 2019-04-16 2023-06-21 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
JP2023106635A (en) 2020-04-17 2023-08-02 中外製薬株式会社 Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
CN114269790B (en) * 2020-07-02 2023-11-24 北京拓界生物医药科技有限公司 anti-FXI/FXIa antibodies, antigen binding fragments thereof and medical application thereof
WO2022002233A1 (en) 2020-07-03 2022-01-06 苏州康宁杰瑞生物科技有限公司 Coagulation factor xi (fxi) binding protein
WO2023070097A2 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
US8236316B2 (en) * 2007-11-21 2012-08-07 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
EP2297207B1 (en) 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
SI2373691T1 (en) * 2008-12-18 2019-05-31 Oregon Health & Science University Anti-fxi antibodies and methods of use
EP2575473B1 (en) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011161099A1 (en) 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2682394A1 (en) 2010-07-09 2014-01-08 Bayer Intellectual Property GmbH 1H-pyrazolo[3,4-b]pyridin-triazine derivatives and their use for the treatment or the prevention of cardiovascular diseases
DE102010040233A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2012143510A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
KR20140074912A (en) 2011-09-01 2014-06-18 에프. 호프만-라 로슈 아게 Pyrrolopyrazine kinase inhibitors
AP2014007541A0 (en) 2011-09-02 2014-03-31 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. YAMASHITA ET AL: "Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 4, no. 7, 1 July 2006 (2006-07-01), pages 1496 - 1501, XP055025684, ISSN: 1538-7933, DOI: 10.1111/j.1538-7836.2006.01973.x *
BAGLIA F A ET AL: "A binding site for thrombin in the apple 1 domain of factor XI", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 7, 16 February 1996 (1996-02-16), pages 3652 - 3658, XP002368765, ISSN: 0021-9258, DOI: 10.1074/JBC.271.7.3652 *
See also references of WO2010080623A2 *
TUCKER ERIK I ET AL: "Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, UNITED STATES, vol. 113, no. 4, 22 August 2008 (2008-08-22), pages 936 - 944, XP009116109, ISSN: 1528-0020, DOI: 10.1182/BLOOD-2008-06-163675 *

Also Published As

Publication number Publication date
PL2373691T3 (en) 2019-07-31
HRP20190605T1 (en) 2019-05-31
AU2009335643B2 (en) 2014-05-29
CA2747519A1 (en) 2010-07-15
WO2010080623A3 (en) 2010-11-18
AU2009335643A1 (en) 2011-07-07
US20130129745A1 (en) 2013-05-23
US20110250207A1 (en) 2011-10-13
EP2373691B1 (en) 2019-01-23
EP2373691A2 (en) 2011-10-12
US8388959B2 (en) 2013-03-05
LT2373691T (en) 2019-05-27
HUE042940T2 (en) 2019-07-29
US8940883B2 (en) 2015-01-27
PT2373691T (en) 2019-05-08
US9637550B2 (en) 2017-05-02
CA2747519C (en) 2019-04-02
CY1121562T1 (en) 2020-05-29
ES2720594T3 (en) 2019-07-23
SI2373691T1 (en) 2019-05-31
TR201904662T4 (en) 2019-05-21
DK2373691T3 (en) 2019-04-15
WO2010080623A2 (en) 2010-07-15
US20150093395A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
IL248723A0 (en) Bcr-complex-specific antibodies and methods of using same
HUE042940T2 (en) Anti-fxi antibodies and methods of use
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2427479A4 (en) Antibodies and methods of use thereof
ZA201005351B (en) Anti-cd79b antibodies and immunoconjugates and methods of use
EG27167A (en) Microemulsifiers and methods of making and using same
HK1171236A1 (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use fcrh5
IL215795A0 (en) Anti-il-17f antibodies and methods of use thereof
EP2347038A4 (en) Methods of humanizing and affinity-maturing antibodies
HK1172896A1 (en) Compounds and methods of use
HK1161094A1 (en) Compounds and methods of use
ZA201107128B (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
IL214433A0 (en) Anti-fgfr3 antibodies and methods using same
HK1149933A1 (en) Diazacarbazoles and methods of use
PT2185719E (en) Anti-rantes antibodies and methods of use thereof
IL209548A0 (en) Diazacarbazoles and methods of use
EP2388320A4 (en) Anti-hs6st2 antibodies and use thereof
IL219136A0 (en) Anti-hepsin antibodies and methods using same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110705

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120928

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/36 20060101AFI20120924BHEP

Ipc: A61K 39/395 20060101ALI20120924BHEP

Ipc: C12N 15/13 20060101ALI20120924BHEP

Ipc: A61P 7/02 20060101ALI20120924BHEP

17Q First examination report despatched

Effective date: 20140310

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602009056862

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07K0016360000

Ipc: A61K0039000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/36 20060101ALI20180625BHEP

Ipc: A61K 39/00 20060101AFI20180625BHEP

INTG Intention to grant announced

Effective date: 20180716

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1090914

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009056862

Country of ref document: DE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20190605

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190408

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2373691

Country of ref document: PT

Date of ref document: 20190508

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190408

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20190605

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E017243

Country of ref document: EE

Effective date: 20190416

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190123

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2720594

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190723

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E042940

Country of ref document: HU

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190401217

Country of ref document: GR

Effective date: 20190620

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009056862

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190605

Country of ref document: HR

Payment date: 20191029

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190123

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20191024

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20191209

Year of fee payment: 11

Ref country code: HU

Payment date: 20191031

Year of fee payment: 11

Ref country code: SK

Payment date: 20191111

Year of fee payment: 11

Ref country code: CY

Payment date: 20191106

Year of fee payment: 11

Ref country code: SE

Payment date: 20191210

Year of fee payment: 11

Ref country code: RO

Payment date: 20191030

Year of fee payment: 11

Ref country code: LT

Payment date: 20191204

Year of fee payment: 11

Ref country code: PT

Payment date: 20191217

Year of fee payment: 11

Ref country code: NO

Payment date: 20191210

Year of fee payment: 11

Ref country code: NL

Payment date: 20191212

Year of fee payment: 11

Ref country code: FI

Payment date: 20191209

Year of fee payment: 11

Ref country code: BG

Payment date: 20191016

Year of fee payment: 11

Ref country code: CZ

Payment date: 20191216

Year of fee payment: 11

Ref country code: MC

Payment date: 20191129

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20191118

Year of fee payment: 11

Ref country code: EE

Payment date: 20191129

Year of fee payment: 11

Ref country code: SI

Payment date: 20191119

Year of fee payment: 11

Ref country code: HR

Payment date: 20191029

Year of fee payment: 11

Ref country code: PL

Payment date: 20191002

Year of fee payment: 11

Ref country code: DK

Payment date: 20191210

Year of fee payment: 11

Ref country code: GR

Payment date: 20191112

Year of fee payment: 11

Ref country code: LV

Payment date: 20191210

Year of fee payment: 11

Ref country code: LU

Payment date: 20191210

Year of fee payment: 11

Ref country code: IS

Payment date: 20191107

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20191125

Year of fee payment: 11

Ref country code: CH

Payment date: 20191213

Year of fee payment: 11

Ref country code: MT

Payment date: 20191219

Year of fee payment: 11

Ref country code: MK

Payment date: 20191028

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20190605

Country of ref document: HR

Effective date: 20201218

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E017243

Country of ref document: EE

Effective date: 20201231

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20201231

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210618

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210101

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1090914

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201218

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 30611

Country of ref document: SK

Effective date: 20201218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210104

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20201218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210630

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201219

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201219

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210707

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20211125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201218

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231130

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231212

Year of fee payment: 15

Ref country code: FR

Payment date: 20231212

Year of fee payment: 15

Ref country code: DE

Payment date: 20231205

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240117

Year of fee payment: 15